Bolt Biotherapeutics, a Bay Area immunocology biotech, completed a $54 million Series B financing led by Pivotal bioVenture Partners of Hong Kong with additional participation from Nan Fung Life Sciences. Pivotal is a Nan Fung investment fund. Bolt is developing systemic immune system treatments to provide immunity-based therapies for cancer. The company will use the funds to advance its lead Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) into the clinic. More details....
Share this with colleagues:
Original Article: Bolt Bio Closes $54 Million Round Led by Hong Kong's Pivotal/Nan Fung